HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by MEIRIK, O. Articles by SIVIN, I. Search for Related Content PubMed PubMed Citation Articles by MEIRIK, O. Articles by SIVIN, I.

Safety and Efficacy of Levonorgestrel Implant, Intrauterine Device, and Sterilization

From the United Nations Development Programme (UNDP)/United Nations Population Fund (UNFPA)/World Health Organization (WHO)/World Bank Special Programme of Research, Development and Research Training in Human Reproduction, Geneva, Switzerland, and The Population Council, New York.

Address reprint requests to: Timothy M. M. Farley, PhD Special Programme of Research Development and Research Training in Human Reproduction World Health Organization 1211 Geneva 27 Switzerland E-mail: farleyt{at}who.int

Objective: To evaluate safety and efficacy of levonorgestrel-releasing contraceptive implants (Norplant; Leiras Oy, Turku, Finland) in developing countries.

Methods: We used controlled cohort methodology. Women attending family planning clinics in eight developing countries selecting Norplant were enrolled, together with women of similar age choosing intrauterine devices (IUDs) or surgical sterilization. Participants were interviewed and examined at semi-annual visits and followed-up for 5 years regardless of change of contraceptive methods. Incidence rate ratios of health events were estimated for initial and current method use.

Results: Altogether, 7977 women initiated Norplant, 6625 IUD, and 1419 sterilization. The overall follow-up rate was 94.6% and 78,323 woman-years of observation were accumulated. Pregnancy rates for Norplant, copper IUDs, and sterilization each averaged less than 1 per 100 woman-years. With two exceptions, no significant excess risk of serious morbidity was detected for Norplant users compared with controls. The incidence of gallbladder disease was higher in women who initiated Norplant use than in controls (rate ratio 1.52, 95% confidence interval [CI] 1.02, 2.27), as was the incidence of hypertension and borderline hypertension in current implant users (rate ratio 1.81; CI 1.12, 2.92). Other new findings were increased risks of respiratory diseases and decreased risks of inflammatory disease of the genital tract in Norplant users compared with IUD users and sterilized women.

Conclusion: The study confirms the safety with respect to serious disease and the high contraceptive efficacy of Nor-plant, copper IUDs, and sterilization.

This article has been cited by other articles:

				I. Saav, A. Aronsson, L. Marions, O. Stephansson, and K. Gemzell-Danielsson Cervical priming with sublingual misoprostol prior to insertion of an intrauterine device in nulliparous women: a randomized controlled trial Hum. Reprod., October 1, 2007; 22(10): 2647 - 2652. [Abstract] [Full Text] [PDF]